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Abstract. The treatment of patients with asthma and comorbidity. Yeryomenko G.V., Bezditko T.V. The increa-
sing prevalence of asthma (A) and diabetes mellitus type 2 (DM2T) necessitates administration of the adequate antia-
sthmatic long-term basic therapy with consideration of comorbid states. The purpose consisted in revealing the 
therapeutic potential of Tiotropium bromide (TB) and L-arginine (Tivortine) in patients having uncontrolled moderately 
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severe asthma in combination with DM2T (A+DM2T). Forty seven A+DM2T patients underwent an in-depth study 
before and after their treatment. They were divided into 2 groups: treatment (group 1, n=28) and comparison (group 2, 
n=19). Both groups received the standard 2-component therapy: budesonide/formoterol fumarate dihydrate – 
160/4.5µg by 2 breaths twice a day and metformin at a dose of 500 mg twice a day. The complex of their basic therapy 
for group 1 additionally included TB (18 µg a day) and arginine hydrochloride preparation (Tivortine® aspartate, 
Yuriya-Farm) orally by 15 ml twice a day during 3 months (90 days). The patients were followed up 3 months and one 
year later. Their general condition demonstrated positive dynamics in both groups, the number of exacerbations in 
group 1 reducing by a factor of 4. The complex use of L-arginine and TB preparations against a background of the 
basic therapy in A+DM2T patients produced a better control over the disease, a more rapid elimination of obstruction 
manifestations, achievement and prolongation of the clinical spirographic remission, an improvement of the quality of 
life, correction of disturbances in haemocoagulation, fibrinolysis and the functional state of endothelium. 
 
Реферат. Лечение больных бронхиальной астмой с коморбидностью. Ерёменко Г.В., Бездетко Т.В. Расту-
щая распространенность бронхиальной астмы (БА) и сахарного диабета 2 типа (СД2Т) обуславливает 
необходимость назначения адекватной противоастматической длительной базисной терапии с учетом 
коморбидных состояний. Целью исследования являлось определение терапевтического потенциала тиотропия 
бромида (ТБ) и L-аргинина (Тивортин) у больных при ассоциации БА среднетяжелого течения, неконтро-
лируемой, в сочетании с СД2Т. Было углубленно обследовано 47 больных БА+СД2Т до и после лечения. Па-
циенты были разделены на 2 группы – основная группа (группа 1, n=28) и группа сравнения (группа 2, n=19). 
Обе группы больных получали стандартную 2-х компонентную терапию – будесонид/формотерола фумарата 
дигидрат – 160/4,5мкг по 2 вдоха дважды в сутки и метформина в дозе 500 мг 2 раза в сутки. Больным 1 
группы в комплекс базисной терапии дополнительно были включены тиотропия бромид (18 мкг в сутки) и 
препарат аргинина гидрохлорид (Тивортин® аспартат «Юрия-Фарм» внутрь по 15 мл 2 раза в сутки, курс 
лечения – 3 мес. (90 дней)). Контрольный осмотр больных был назначен через 3 месяца и один год. Уста-
новлена положительная динамика в самочувствии больных в обеих группах, а количество обострений в группе 
1 уменьшилось в 4 раза. Комплексное применение препаратов L-аргинина и тиотропия бромида на фоне ба-
зисной терапии у больных БА+СД2Т приводит к лучшему контролю над заболеванием, более быстрому ус-
транению проявлений обструкции, достижению и увеличению продолжительности клинико-спирографической 
ремиссии, улучшению качества жизни, коррекции нарушений гемокоагуляции, фибринолиза и функционального 
состояния эндотелия. 
 
Treatment of comorbid states is one of important 
problems in medical practice. Ageing of population, 
bad habits, hypodynamia, irrational nutrition and a 
worsening ecological situation create conditions for 
a constant stress of the adaptive and biochemical 
mechanisms in the organism of the modern man 
with a resultant formation of several diseases in it. 
The prevalence of comorbid pathology in patients 
averages 78.6%, this condition occurring in 82% of 
cases in women and 72% in men [2]. The number of 
comorbid diseases in one patient considerably inc-
reases with age. For example, researchers have re-
vealed that multimorbidity rises from 10% at the 
age, which does not exceed 19 years, to 80% in 
people at the age of 80 and older [14]. The simul-
taneous presence of several diseases affects each of 
them, aggravating their course, facilitating an earlier 
formation of complications and creating difficulties 
for therapy. The risk of death in case of two con-
comitant diseases is 5-10% and rises up to 70-80%, 
when their number increases up to five. Especially 
noteworthy is a combination of diseases, which have 
common or close aetiological and pathogenetic fac-
tors. The European standard of the GINA (2016 
revision) for asthma contains a list of concomitant 
diseases, which can affect the course of the main 
pathology in a patient so much that the basic treat-
ment is insufficient and becomes ineffective. Such 
diseases include rhinitis and rhinosinusitis, gastro-
oesophageal reflux disease, night apnoea as well as 
diabetes mellitus and obesity [6, 19, 20]. 
It is possible to achieve the full or partial control 
of asthma (A) in the majority of patients under con-
ditions of the correct assessment of its severity, the 
available level of asthma control and administration 
of the adequate antiasthmatic long-term basic the-
rapy with consideration of comorbid states [21]. 
Pharmacotherapy is an essential component of treat-
ment for any asthma. According to contemporary 
views on treatment of asthma, the main drugs for 
maintaining control over symptoms are provided by 
inhaled glucocorticosteroids (IGCS) with the per-
sonalized approach and attempts to separate single 
phenotypes of the disease with a subsequent deve-
lopment of the individual treatment plan (GINA, 
2017) [15]. At present there is no need to prove ad-
vantages of combined therapy in fixed combinations 
of IGCS with long-acting β2agonists (LABA) over 
monotherapy with IGCS. 
Active searches are constantly made for rela-
tionships between the phenotype, genotype, mecha-
nisms of the disease development and appearance of 
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concomitant pathology, which may result from the 
therapy given. In future the above will make it 
possible to develop an algorithm for administering 
drugs depending upon the variant of the disease 
course [9, 20]. But it is believed that the most es-
sential and clinically significant feature in the course 
of asthma in patients with diabetes mellitus type 2 
(DM2T) consists in their overweight and obesity, 
thereby hindering the expected decrease of the 
disease severity in the process of treatment [19, 16]. 
Besides, the patients from this group demonstrate 
less efficiency of their basic therapy with use of 
IGCS; this fact often requires an increase in the daily 
dose of the used drugs with a resultant disturbance 
of carbohydrate metabolism [10, 13, 17]. In this con-
nection it is necessary to study further the mecha-
nisms of appearance of resistance to treatment and 
progression of asthma, combined with DM2T. The 
problem necessitates a multidimensional approach to 
diagnosis with inclusion of inflammatory markers, 
which are required for correction of the treatment. 
Purpose – to reveal the therapeutic potential of 
Tiotropium bromide (TB) and L-arginine (Tivortine) 
in patients having uncontrolled moderately severe 
asthma in combination with DM2T (A+DM2T) on 
the basis of study of their influence on the functional 
state of lungs, the endothelial function and 
glucometabolic disturbances.  
MATERIALS AND METHODS 
The study involved 47 patients with A+DM2T 
before and after their treatment. The control group 
consisted of 20 apparently healthy people. The pa-
tients’ diagnosis and treatment were made in com-
pliance with Order No. 868 of the Ministry of Health 
of Ukraine dated October 8, 2013 “On Approval and 
Implementation of Medical-Technological Docu-
ments on Standardization of Medical Aid in 
Asthma” [8]. The diagnosis and treatment of conco-
mitant DM2T were made by a skilled professional in 
endocrinology according to effective Ukrainian pro-
tocols [7]. The patients were divided into 2 groups: 
the treatment group (group 1, n=28) and the com-
parison group (group 2, n=19). Both groups of pa-
tients received the standard 2-component therapy: 
budesonide/formoterol fumarate dehydrate – 160/4.5 
µg (IGCS+LABA) in a dry powder inhaler by 2 
breaths twice a day and metformin at a dose of 500 
mg 2 times a day. Salbutamol sulphate in a metered 
dose inhaler (100 µg “on demand”) was used as an 
“emergency care” drug. The complex of their basic 
therapy for patients from group 1 additionally 
included TB (18 µg a day) and arginine hydro-
chloride preparation (Tivortine® aspartate, Yuriya-
Farm) orally by 15 ml 2 times a day, the course of 
treatment lasted 3 months (90 days). The patients 
were followed up 3 months and one year later. 
The patients’ personal data included their gender, 
age, weight, body mass index (BMI) and history of 
exacerbations. On day 1 as well as after 3 and 12 
months since the beginning of therapy the following 
examinations were made: forced expiratory volume 
in the first second (FEV1), forced vital capacity 
(FVC), forced expiratory volume (FEV), Tiffeneau-
Pinelli index (FEV1/FVC), forced expiratory flow on 
the levels of 25, 50 and 75% (FEF25, FEF50, 
FEF75), as well as such general clinical and bioche-
mical indices as glycated haemoglobin (HbAlc,%) 
and fasting blood glucose level (r) were analysed. 
The content of monocyte chemoattractant protein-1 
(MCP-1) and matrix metalloproteinase-9 (MMP-9) 
in blood serum was determined by the method of 
enzyme immunoassay (ELISA) with help of 
“HUMAN МСР-1” and “HUMAN ММР-9”kits 
(eBioscience, Austria),von Willebrand factor (VWF) 
by the photoelectric colourimetric method [1] and 
nitric oxide metabolites, S-nitrosothiols (S-NO) by 
the spectrophotometric method modified by Ko-
val’ova O.M. [4]. The state of external respiration 
(ER) was assessed on the basis of the forced 
respiration curve, which was registered on a Spi-
roCom spirograph (Ukraine). The following para-
meters were assessed: FVC, FEV1, FEF25, FEF50, 
FEF75. The assessment of the severity of asthma at-
tacks and the level of the disease control was forma-
lized and made according to the Asthma Control 
Questionnaire (ACQ) [11] and Asthma Quality of 
Life Questionnaire (AQLQ) [8]. The study findings 
were statistically processed with use of SPSS 19 
program for Windows (IBM, USA). Quantitative va-
riables were described by the following parameters: 
the median (Me) and the 25thand 75thpercentiles (Me 
[25%-75%]). In order to reveal differences between 
independent samples, the Mann-Whitney U test was 
used. The normality of data distribution was ana-
lysed with help of the Shapiro-Wilk test. 
RESULTS AND DISCUSSION 
Analysis of the findings revealed that after 12 
months of the regular taking of the IGCS/LABA 
combination most of the ER indices in the examined 
groups tended to improve. But for the majority of 
characteristics these changes were not statistically 
significant (Fig. 1). Values of inflammatory markers 
in patients from group 1 decreased: МСР-1 from 
806.14 [768.36-904.37] ng/ml to 534.50 [430.71-
631.70] ng/ml (р=0.013), ММР-9 from 788.5 [336.14-
933.31] ng/ml to 576.50 [343.2-645.74] ng/ml 
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(р=0.001); the above was accompanied with an 
improvement of the endothelial function: a reduction 
of VWF (Fig. 2) and an elevation of S-NO (Fig. 3). 
At the same time, there were no reliable changes of 
these indices in patients from group 2 (Figs. 4 and 
5). Such a reduction of VWF as a decrease of the 
vasospastic state of endothelium under the effect of 
Tivortine and TB was revealed. At the same time, 
especially noteworthy is an increased content of 
nitric oxide metabolites (S-nitrosothiols) as indi-
cators of functioning of vasodilatory mechanisms of 
cellular interactions. The latter fact can be regarded 
as the compensatory intensification of vasodilatory 
activity in response to a reduced action of VWF. 
Results of analysis of carbohydrate metabolism re-
liably demonstrated decreases of HbAlc% (from 
7.50 [7.07-7.90]% to 6.3[5.95-6.72]%, р=0.01) and 
the glycaemic load level (from 6.90 [6.02-
7.40] mmol/l to 6.01[5.20-6.61] mmol/l, р=0.03) in 
patients from group 1 and absence of reliable 
changes in group 2. The number of A+DM2T exa-
cerbations during 12 months of follow-up was calcu-
lated on the basis of personal encounters of the 
patients and data of analysis of medical documents. 
Under the influence of the chosen treatment the 
number of exacerbations in group 1 decreased by a 
factor of 4 (down to [1.0-2.0] cases a year), and 
these changes were reliable (p=0.001). In group 2, 
on the contrary, this index improved but remained 
unreliable, it causing involvement into the study 
from 4.0 [4.0-5.0] cases a year to 3.0 [2.5-4.5] cases 
a year (р=0.607). The quality of life in patients from 
groups 1 and 2 improved (respectively, the general 
quality of life by 46% and 29%, the physical com-
ponent of health by 34% and 18%, the mental com-
ponent of health by 46% and 21%), the degree of 
asthma control increasing in patients from group 1 
by 21% and in patients from group 2 by 12% by 
ACQ data. Analysis of anthropometric data changes 
showed a decrease of BMI in group 1 from 28.5 [26.7-
32.5] kg/m2 to 27.01 [24.59-30.3] kg/m2, (р=0.001). 
 
 
Fig. 1. The dynamics of changes in ER under the effect of treatment 
 
The findings clearly demonstrate that it is rea-
sonable to administer the combination of L-arginine 
and TB against a background of the basic therapy to 
patients with A+DM2T for reducing a possibility of 
exacerbations and improving the prognosis for the 
course of the disease [12, 18, 21]. 
It is known that the use of Tivortine in treatment 
of patients produces an effect on the endothelial 
function and improves its state, catalyzes the syn-
thesis of nitric oxide in endotheliocytes, increases 
the level of cyclic guanosine monophosphate 
(cGMP) in vascular endothelium, decreases activa-
tion and adhesion of leukocytes and thrombocytes to 
vascular endothelium and inhibits the synthesis of 
MCP-1 [3, 5, 6]. 
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Fig. 2. The dynamics of changes in VWF under the effect of treatment (%) 
 




Fig. 3. The dynamics of changes inS-NO under the effect of treatment (µmol/l) 
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Fig. 4. The dynamics of the number of complications per year under the effect of treatment 
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CONCLUSIONS 
1. The complex use of L-arginine and TB pre-
parations against a background of the basic therapy 
in patients with asthma combined with DM2T re-
sulted in correction of disturbances in haemo-
coagulation, fibrinolysis and the functional state of 
endothelium with a better control over the disease. 
2. When treating patients with asthma combined 
with DM2T it is reasonable to include L-arginine 
and TB preparations into the complex therapy due to  
 
the positive effect on the patients’ general condition, 
a more rapid elimination of obstruction mani-
festations, achievement and prolongation of the cl-
inical spirographic remission, and an improvement 
of the quality of life. 
3. Comparison of the patients’ indices from 
groups 1 and 2 before the treatment, after 3 months 
and after 1 year. 
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